BRCA1 and breast carcinoma: In this context, the PrECOG 0105 phase II study of gemcitabine and carboplatin plus iniparib as neoadjuvant therapy for TNBC and BRCA1/2 mutation-associated breast cancer, revealed that combination of gemcitabine, carboplatin, and iniparib is active in the treatment of early-stage triple-negative and BRCA1/2 mutation-associated breast cancer.